| Autor: |
Yulong Liu, Yansong Qiao, Miaoli Zhou, Jiandong Guo, Yinsheng Lin, Wanghai Li, Chao An, Chengzhi Li |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Cancer Medicine, Vol 12, Iss 5, Pp 5436-5449 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2045-7634 |
| DOI: |
10.1002/cam4.5366 |
| Popis: |
Abstract Purpose Evaluate the efficacy and safety of triple therapeutic method (Hepatic Aarterial Infusion Chemotherapy—HAIC, lenvatinib and sequential ablation) in the treatment for Advanced Hepatocellular carcinoma (Ad‐HCC). Materials and Methods From November 2018 to June 2021, data from 150 consecutive Ad‐HCC patients were collected. All patients received HAIC combined with lenvatinib (H‐L group, n = 97) or HAIC combined with lenvatinib and sequential ablation (H‐L‐A group, n = 53). Complications, overall survival (OS), progression‐free survival (PFS) and intrahepatic progression‐free survival (IPFS) were compared between both groups. Results No significant differences of baseline characteristics were found between groups. The time of median follow‐up was 17.8 months (range, 6.8, 37.6 months). In comparison to the H‐L group, the H‐L‐A group patients showed significantly longer median OS (>30 months vs 13.6 months, respectively; p = 0.010), PFS (12.8 vs. 5.6 months, respectively; p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
